(Q28475917)

https://www.ncbi.nlm.nih.gov/pubmed/?term=21049059

comparative study

1 reference

https://www.ncbi.nlm.nih.gov/pubmed/?term=21049059

title

Geographical variation in the response of visceral leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial (English)

0 references

main subject

infectious disease

0 references

multicenter clinical trial

0 references

East Africa

0 references

visceral leishmaniasis

1 reference

1 reference

Eyasu Makonnen

11

0 references

Asrat Hailu

1

object named as

Asrat Hailu

0 references

author name string

Ahmed Musa

2

0 references

Monique Wasunna

3

0 references

Manica Balasegaram

4

0 references

Sisay Yifru

5

0 references

Getahun Mengistu

6

0 references

Zewdu Hurissa

7

0 references

Workagegnehu Hailu

8

0 references

Teklu Weldegebreal

9

0 references

Samson Tesfaye

10

0 references

Eltahir Khalil

12

0 references

Osama Ahmed

13

0 references

Ahmed Fadlalla

14

0 references

Ahmed El-Hassan

15

0 references

Muzamil Raheem

16

0 references

Marius Mueller

17

0 references

Yousif Koummuki

18

0 references

Juma Rashid

19

0 references

Jane Mbui

20

0 references

Geoffrey Mucee

21

0 references

Simon Njoroge

22

0 references

Veronica Manduku

23

0 references

Alice Musibi

24

0 references

Geoffrey Mutuma

25

0 references

Fredrick Kirui

26

0 references

Hudson Lodenyo

27

0 references

Dedan Mutea

28

0 references

George Kirigi

29

0 references

Tansy Edwards

30

0 references

Peter Smith

31

0 references

Lawrence Muthami

32

0 references

Catherine Royce

33

0 references

Sally Ellis

34

0 references

Moses Alobo

35

0 references

Raymond Omollo

36

0 references

Josephine Kesusu

37

0 references

Rhoda Owiti

38

0 references

John Kinuthia

PLoS Neglected Tropical Diseases

39

0 references

language of work or name

English

0 references

publication date

26 October 2010

0 references

published in

0 references

volume

4

0 references

issue

10

0 references

page(s)

e709

0 references

copyright license

Creative Commons Attribution 2.5 Generic

0 references

on focus list of Wikimedia project

ScienceSource

0 references

cites work

Visceral leishmaniasis: new health tools are needed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Drug resistance in leishmaniasis

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Visceral leishmaniasis in eastern Africa--current status

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Injectable paromomycin for Visceral leishmaniasis in India

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Royal Society of Tropical Medicine and Hygiene joint meeting with Médecins Sans Frontières at Manson House, London, 20 March 2003: field research in humanitarian medical programmes. Médecins Sans Frontières interventions against kala-azar in the Sud

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Leishmaniasis. Public health aspects and control

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Sodium stibogluconate cardiotoxicity and safety of generics

2 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000709

The economic impact of visceral leishmaniasis on households in Bangladesh

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000709

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000709

Treatment of visceral leishmaniasis with injectable paromomycin (aminosidine). An open-label randomized phase-II clinical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000709

A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PNTD.0000709

Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases.

27 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2964287

10.1371/JOURNAL.PNTD.0000709

27 November 2018

Identifiers

DOI

1 reference

1 reference

1 reference

PubMed publication ID

21049059

1 reference